首页> 美国卫生研究院文献>Future Medicinal Chemistry >Leaving the lysosome behind: novel developments in autophagy inhibition
【2h】

Leaving the lysosome behind: novel developments in autophagy inhibition

机译:抛弃溶酶体:自噬抑制的新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The search for a single silver bullet for the treatment of cancer has now been overshadowed by the identification of multiple therapeutic targets unique to each malignancy and even to each patient. In recent years, autophagy has emerged as one such therapeutic target. In response to both therapeutic and oncogenic stress, cancer cells upregulate and demonstrate an increased dependence upon this intracellular recycling process. Particularly in malignancies that currently lack targeted therapeutic options, autophagy inhibitors are the next hopeful prospects for the treatment of this disease. In this review, we discuss the rapid evolution of autophagy inhibitors from early lysosomotropic agents to next-generation lysosome-targeted drugs and beyond.
机译:现在,对于每个恶性肿瘤,甚至对于每个患者,唯一的多个治疗靶标的识别已经掩盖了寻找单一的治疗癌症的银弹。近年来,自噬已经成为一种这样的治疗靶标。响应于治疗压力和致癌压力,癌细胞上调并显示出对该细胞内再循环过程的依赖性增加。特别是在目前缺乏靶向治疗选择的恶性肿瘤中,自噬抑制剂是该疾病治疗的下一个有希望的前景。在这篇综述中,我们讨论了自噬抑制剂从早期溶溶体药物向下一代溶酶体靶向药物的快速发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号